The contract’s dispute resolution process for determining whether a drug qualifies for milestone payments is an arbitration provision and not one regarding expert determination, according to an unredacted opinion released Monday by the Delaware Chancery Court.
“The Agreement makes this clear by specifically marking a distinction between an ‘expert’ and an ‘arbitrator’ in other provisions,” Delaware Superior Court Judge Patricia A. Winston said in an opinion originally ...